Gene transfer to the CNS using recombinant adeno-associated virus

Current Protocols in Microbiology

Volumn , Issue SUPPL.29, 2013, Pages

  Stoica, Lorelei ^a   S Ahmed, Seemin ^a   Gao, Guangping ^a,b   Sena Esteves, Miguel ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b SICHUAN UNIVERSITY   (China)

Author keywords

AAV; Intracranial; Intravascular; Neonate stereotaxic

Indexed keywords

ALCOHOL; EYE DROPS; KETAMINE; PARVOVIRUS VECTOR; POVIDONE IODINE; RECOMBINANT ADENO ASSOCIATED VIRUS VECTOR; UNCLASSIFIED DRUG; XYLAZINE; ALPHA 1 ANTITRYPSIN; EOSIN; FIREFLY LUCIFERASE; HEMATOXYLIN; MICRORNA;

ADENO ASSOCIATED VIRUS; ANESTHESIA INDUCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN TISSUE; CELLULAR DISTRIBUTION; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; CRANIOTOMY; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENETIC PROCEDURES; GENETIC TRANSDUCTION; HISTOLOGY; NEWBORN; NONHUMAN; PRIORITY JOURNAL; STEREOTACTIC PROCEDURE; THAWING; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; ANIMAL; GENE VECTOR; GENETICS; LIVER; METHODOLOGY; MOUSE; CLEARANCE; COPY NUMBER VARIATION; ENZYME ACTIVITY; FLUORESCENCE IMAGING; HISTOPATHOLOGY; IMMUNE RESPONSE; LIVER BIOPSY; LIVER HISTOLOGY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; VIRUS GENOME; VIRUS PARTICLE; WESTERN BLOTTING; HAZARDOUS WASTE; IMMUNOHISTOCHEMISTRY; LUNG; PHYSIOLOGY; VIROLOGY; VIRUS REPLICATION;

ANIMALS; DEPENDOVIRUS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; LIVER; MICE; TRANSDUCTION, GENETIC; CONTAINMENT OF BIOHAZARDS; IMMUNOHISTOCHEMISTRY; LUNG; TRANSGENES; VIRUS REPLICATION; CENTRAL NERVOUS SYSTEM;

MLCS; MLOWN;

EID: 84880689034     PISSN: 19348525     EISSN: 19348533     Source Type: Journal    
DOI: 10.1002/9780471729259.mc14d05s29     Document Type: Article

References (46)

1. Afione, S.A., Conrad, C.K., and Flotte, T.R. 1995. Gene therapy vectors as drug delivery systems. Clin. Pharmacokinet. 28:181-189.
2. Asokan, A., Schaffer, D.V., and Samulski, R.J. 2012. TheAAVvector toolkit: Poised at the clinical crossroads. Mol. Ther. 20:699-708.
3. Bankiewicz, K.S., Eberling, J.L., Kohutnicka, M., Jagust, W., Pivirotto, P., Bringas, J., Cunningham, J., Budinger, T.F., and Harvey-White, J. 2000. Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp. Neurol. 164:2-14.
4. Bell, C.L., Gurda, B.L., Van Vliet, K., Agbandje-McKenna, M., and Wilson, J.M. 2012. Identification of the galactose binding domain of the adeno-associated virus serotype 9 capsid. J. Virol. 86:7326-7333.
5. Bevan, A.K., Duque, S., Foust, K.D.,Morales, P.R., Braun, L., Schmelzer, L., Chan, C.M., McCrate, M., Chicoine, L.G., Coley, B.D., Porensky, P.N., Kolb, S.J., Mendell, J.R., Burghes, A.H., and Kaspar, B.K. 2011. Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders. Mol. Ther. 19:1971-1980.
6. Boutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M.F., and Masurier, C. 2010. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: Implications for gene therapy using AAV vectors. Hum. Gene Ther. 21:704-712.
7. Burger, C., Gorbatyuk, O.S., Velardo, M.J., Peden, C.S., Williams, P., Zolotukhin, S., Reier, P.J., Mandel, R.J., and Muzyczka, N. 2004. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol. Ther. 10:302-317.
8. Calcedo, R., Vandenberghe, L.H., Gao, G., Lin, J., and Wilson, J.M. 2009. Worldwide epidemiology of neutralizing antibodies to adenoassociated viruses. J. Infect. Dis. 199:381-390.
9. Cearley, C.N. and Wolfe, J.H. 2006. Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. Mol. Ther. 13:528-537.
10. Cearley, C.N. and Wolfe, J.H. 2007. A single injection of an adeno-associated virus vector into nuclei with divergent connections results in widespread vector distribution in the brain and global correction of a neurogenetic disease. J. Neurosci. 27:9928-9940.
11. Cearley, C.N., Vandenberghe, L.H., Parente, M.K., Carnish, E.R., Wilson, J.M., and Wolfe, J.H. 2008. Expanded repertoire of AAV vector serotypes mediate unique patterns of transduction in mouse brain. Mol. Ther. 16:1710-1718.
12. Chen, Y.H., Chang, M., and Davidson, B.L. 2009. Molecular signatures of disease brain endothelia provide new sites for CNS-directed enzyme therapy. Nat. Med. 15:1215-1218.
13. Cotugno, G., Annunziata, P., Tessitore, A., O'Malley, T., Capalbo, A., Faella, A., Bartolomeo, R., O'Donnell, P., Wang, P., Russo, F., Sleeper, M.M., Knox, V.W., Fernandez, S., Levanduski, L., Hopwood, J., De Leonibus, E., Haskins,M., andAuricchio,A. 2011. Long-term amelioration of feline Mucopolysaccharidosis VI after AAV-mediated liver gene transfer. Mol. Ther. 19:461-469.
14. Cunningham, J., Oiwa, Y., Nagy, D., Podsakoff, G., Colosi, P., and Bankiewicz, K.S. 2000. Distribution of AAV-TK following intracranial convection-enhanced delivery into rats. Cell Transplant. 9:585-594.
15. Cunningham, J., Pivirotto, P., Bringas, J., Suzuki, B., Vijay, S., Sanftner, L., Kitamura, M., Chan, C., and Bankiewicz, K.S. 2008. Biodistribution of adeno-associated virus type-2 in nonhuman primates after convection-enhanced delivery to brain. Mol. Ther. 16:1267-1275.
16. Eberling, J.L., Jagust, W.J., Christine, C.W., Starr, P., Larson, P., Bankiewicz, K.S., and Aminoff, M.J. 2008. Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 70:1980-1983.
17. Foust, K.D., Nurre, E., Montgomery, C.L., Hernandez, A., Chan, C.M., and Kaspar, B.K. 2009. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol. 27:59-65.
18. Foust, K.D.,Wang, X., McGovern, V.L., Braun, L., Bevan, A.K., Haidet, A.M., Le, T.T., Morales, P.R., Rich, M.M., Burghes, A.H., and Kaspar, B.K. 2010. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat. Biotechnol. 28:271-274.
19. Gagliardi, C. and Bunnell, B.A. 2009. Large animal models of neurological disorders for gene therapy. ILAR J. 50:128-143.
20. Gao, G., Vandenberghe, L.H., and Wilson, J.M. 2005. New recombinant serotypes of AAV vectors. Curr. Gene Ther. 5:285-297.
21. Gray, S.J., Matagne, V., Bachaboina, L., Yadav, S., Ojeda, S.R., and Samulski, R.J. 2011. Preclinical differences of intravascular AAV9 delivery to neurons and glia: A comparative study of adult mice and nonhuman primates. Mol. Ther. 19:1058-1069.
22. Hadaczek, P., Mirek, H., Bringas, J., Cunningham, J., and Bankiewicz, K. 2004. Basic fibroblast growth factor enhances transduction, distribution, and axonal transport of adeno-associated virus type 2 vector in rat brain. Hum. Gene Ther. 15:469-479.
23. Hadaczek, P., Kohutnicka, M., Krauze, M.T., Bringas, J., Pivirotto, P., Cunningham, J., and Bankiewicz, K. 2006. Convection-enhanced delivery of adeno-associated virus type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain. Hum. Gene Ther. 17:291-302.
24. Hwu, W.L., Muramatsu, S., Tseng, S.H., Tzen, K.Y., Lee, N.C., Chien, Y.H., Snyder, R.O., Byrne, B.J., Tai, C.H., andWu, R.M. 2012. Gene therapy for aromatic L-amino acid decarboxylase deficiency. Sci. Transl. Med. 4:134ra161.
25. Janson, C., McPhee, S., Bilaniuk, L., Haselgrove, J., Testaiuti, M., Freese, A., Wang, D.J., Shera, D., Hurh, P., Rupin, J., Saslow, E., Goldfarb, O., Goldberg, M., Larijani, G., Sharrar, W., Liouterman, L., Camp, A., Kolodny, E., Samulski, J., and Leone, P. 2002. Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Hum. Gene Ther. 13:1391-1412.
26. Kaplitt, M.G., Leone, P., Samulski, R.J., Xiao, X., Pfaff, D.W., O'Malley, K.L., and During, M.J. 1994. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat. Genet. 8:148-154.
27. Kaplitt, M.G., Feigin, A., Tang, C., Fitzsimons, H.L., Mattis, P., Lawlor, P.A., Bland, R.J., Young, D., Strybing, K., Eidelberg, D., and During, M.J. 2007. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: An open label, phase I trial. Lancet 369:2097-2105.
28. Kells, A.P., Hadaczek, P., Yin, D., Bringas, J., Varenika, V., Forsayeth, J., and Bankiewicz, K.S. 2009. Efficient gene therapy-based method for the delivery of therapeutics to primate cortex. Proc. Natl. Acad. Sci. U.S.A. 106:2407-2411.
29. Klein, R.L., Dayton, R.D., Leidenheimer, N.J., Jansen, K., Golde, T.E., and Zweig, R.M. 2006. Efficient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fluorescent proteins. Mol. Ther. 13:517-527.
30. Klein, R.L., Dayton, R.D., Tatom, J.B., Henderson, K.M., and Henning, P.P. 2008. AAV8, 9, Rh10, Rh43 vector gene transfer in the rat brain: Effects of serotype, promoter and purification method. Mol. Ther. 16:89-96.
31. Mastakov, M.Y., Baer, K., Xu, R., Fitzsimons, H., and During, M.J. 2001. Combined injection of rAAV with mannitol enhances gene expression in the rat brain. Mol. Ther. 3:225-232.
32. Monteilhet, V., Saheb, S., Boutin, S., Leborgne, C., Veron, P., Montus, M.F., Moullier, P., Benveniste, O., and Masurier, C. 2011. A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adenoassociated virus (AAV) types 1, 2, 6, and 8. Mol. Ther. 19:2084-2091.
33. Münch, R.C., Janicki, H., Völker, I., Rasbach, A., Hallek, M., Büning, H., and Buchholz, C.J. 2013. Displaying high-affinity ligands on adeno-associated viral vectors enables tumor cell-specific and safe gene transfer. Mol. Ther. 21:109-118.
34. Muramatsu, S., Fujimoto, K., Kato, S., Mizukami, H.,Asari, S., Ikeguchi,K., Kawakami, T., Urabe, M., Kume, A., Sato, T., Watanabe, E., Ozawa, K., and Nakano, I. 2010. A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease. Mol. Ther. 18:1731-1735.
35. Nguyen, J.B., Sanchez-Pernaute, R., Cunningham, J., and Bankiewicz, K.S. 2001. Convectionenhanced delivery of AAV-2 combined with heparin increases TK gene transfer in the rat brain. Neuroreport 12:1961-1964.
36. Paxinos, G. and Franklin, K.B.J. 2001. The Mouse Brain in Stereotaxic Coordinates, 2nd ed. Academic Press, San Diego. Rapti, K., Louis-Jeune, V., Kohlbrenner, E., Ishikawa,K., Ladage,D., Zolotukhin, S., Hajjar, R.J., and Weber, T. 2012. Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models. Mol. Ther. 20:73-83.
37. Salegio, E.A., Samaranch, L., Kells, A.P., Mittermeyer, G., San Sebastian, W., Zhou, S., Beyer, J., Forsayeth, J., and Bankiewicz, K.S. 2013. Axonal transport of adeno-associated viral vectors is serotype-dependent. Gene Ther. 20:348-352.
38. Samaranch, L., Salegio, E.A., San Sebastian, W., Kells, A.P., Foust, K.D., Bringas, J.R., Lamarre, C., Forsayeth, J., Kaspar, B.K., and Bankiewicz, K.S. 2012. Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates. Hum. Gene Ther. 23:382-389.
39. Shen, S., Bryant, K.D., Brown, S.M., Randell, S.H., and Asokan, A. 2011. Terminal N-linked galactose is the primary receptor for adeno-associated virus 9. J. Biol. Chem. 286:13532-13540.
40. Snyder, B.R., Gray, S.J., Quach, E.T., Huang, J.W., Leung, C.H., Samulski, R.J., Boulis,N.M., and Federici, T. 2011. Comparison of adenoassociated viral vector serotypes for spinal cord and motor neuron gene delivery. Hum. Gene Ther. 22:1129-1135.
41. Sondhi, D., Hackett, N.R., Peterson, D.A., Stratton, J., Baad, M., Travis, K.M., Wilson, J.M., and Crystal, R.G. 2007. Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adenoassociated virus vector. Mol. Ther. 15:481-491.
42. van der Marel, S., Comijn, E.M., Verspaget, H.W., van Deventer, S., van den Brink, G.R., Petry, H., Hommes, D.W., and Ferreira, V. 2011. Neutralizing antibodies against adeno-associated viruses in inflammatory bowel disease patients: Implications for gene therapy. Inflamm. Bowel Dis. 17:2436-2442
43. Worgall, S., Sondhi, D., Hackett, N.R., Kosofsky, B., Kekatpure, M.V., Neyzi, N., Dyke, J.P., Ballon, D., Heier, L., Greenwald, B.M., Christos, P., Mazumdar, M., Souweidane, M.M., Kaplitt, M.G., and Crystal, R.G. 2008. Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum. Gene Ther. 19:463-474.
44. Xie, J., Xie, Q., Zhang, H., Ameres, S.L., Hung, J.H., Su, Q., He, R., Mu, X., Seher Ahmed, S., Park, S., Kato, H., Li, C., Mueller, C., Mello, C.C., Weng, Z., Flotte, T.R., Zamore, P.D., and Gao, G. 2011. MicroRNA-regulated, systemically delivered rAAV9: A step closer to CNS-restricted transgene expression. Mol. Ther. 19:526-535.
45. Yang, B., Cao, C., Zhang, H., Su, Q., Ahmed, S.S., Zhong, L., He, R., Sena-Esteves, M., Flotte, T.R., Brown, R., Xu, Z., and Guangping, G. 2012. Intravasuclar delivery of rAAVrh.8 generates widespreading transduction of neuronal and glial cell types in the adult mouse central nervous system. American Society of Gene & Cell Therapy, 15th Annual Meeting. May 16-19, 2012, Philadelphia, Penn.
46. Zhang, H., Yang, B., Mu, X., Ahmed, S.S., Su, Q., He, R.,Wang, H.,Mueller, C., Sena-Esteves, M., Brown, R., Xu, Z., and Gao, G. 2011. Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. Mol. Ther. 19:1440-1448.